Desire trial results at PT-141 MD
The combination experiment raised my interest. The women’s trials put a harder question in front of it: how much improvement did treatment bring?
RECONNECT outcomes
The two randomized Phase 3 RECONNECT trials studied premenopausal women with acquired, generalized HSDD over 24 weeks. Bremelanotide improved the desire domain of the Female Sexual Function Index and reduced distress about low desire compared with placebo. These were the co-primary endpoints, the outcomes the trials were designed to test.
Satisfying sexual events did not separate from placebo in the pooled analyses. That leaves an awkward but worthwhile result: the questionnaire changes and the event count tell different parts of the story. Relief from distress can matter even if a count stays still; the count also limits how broadly an improvement can be described.
I’d take a modest benefit seriously. I’d also resist describing it as a general transformation of sexual life. Neither the population nor the measured outcomes gives that claim enough room.
After the blinded trials
A 52-week open-label extension followed premenopausal women with HSDD who continued into longer-term treatment. Desire improvements were maintained and no new safety signals were identified. The treatment-related adverse events included nausea at 40.4%, flushing at 20.6% and headache at 12.0%.
Open-label means the participants and investigators knew which treatment was being given. That makes the extension useful for following continued exposure, while the original blinded comparison remains the stronger place to judge benefit against placebo.
Continuing participants tell a particular story about longer-term treatment.
A subgroup analysis also examined age, BMI, hormonal contraceptive use and HSDD duration within the premenopausal trial population. I read those comparisons as questions within that population. They do not establish an effect in groups the trials did not study.
Central and peripheral pharmacology
The neurobiology review describes central melanocortin pathways, particularly MC4R, as the proposed basis for bremelanotide’s effect on desire. PDE5 inhibitors such as sildenafil act peripherally on blood flow. That distinction explains why the early combination study asked whether the approaches could work together.
The animal evidence has its own precise boundaries. In female rats, PT-141 increased sexual solicitation without changing lordosis, pacing or general motor activity. Solicitation is partner-seeking behaviour; a rat’s behaviour cannot stand in for a person’s report of desire or distress.
I prefer the mechanism as an explanation to investigate. The human outcomes still have to earn the clinical claim.
The male studies
The 2004 intranasal study and a subcutaneous study explored erectile responses in men. They belong to the development history; the approved indication remains acquired, generalized HSDD in premenopausal women.
A later 2008 study in men whose erectile dysfunction had responded inadequately to sildenafil has a 2023 Expression of Concern. Its findings are disputed. That editorial warning substantially reduces the weight I’m willing to put on it.
The combination question interests me enough to deserve dependable evidence. An attractive theory cannot repair uncertainty about the study that appears to support it.